Filter Results:
(605)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (249)
- Research (605)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (249)
- Research (605)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 05 Jul 2006
- Research & Ideas
The Accidental Innovator
for a new ulcer drug and discover one in a surprising way, that's not quite as amazing as if you are looking for a new ulcer drug and discover instead a new artificial sweetener (this is how Aspartame,... View Details
Keywords: by Sarah Jane Gilbert
- 25 Aug 2003
- Research & Ideas
Why IT Does Matter
Radio-frequency identification devices for grocery stores, smart cards, and automated ordering systems for hospital physicians are all examples of new process targets that technologies will soon address. In the more distant future we will see the improved creation of... View Details
Keywords: by F. Warren McFarlan & Richard L. Nolan
- 23 May 2023
- Research & Ideas
Lessons on Life, Graffiti, and Value: 'It's in That Darkness That You Can Actually Develop and Evolve'
said. Graffiti was also a form of escape. In the 1980s and ’90s, gang violence and drugs were rampant in Los Angeles. For young people seeking a different path, graffiti crews offered an identity that was of the streets but not confined... View Details
Keywords: by Christina Pazzanese, Harvard Gazette
- 29 Jan 2021
- Op-Ed
How Influencers, Celebrities, and FOMO Can Win Over Vaccine Skeptics
of the much harsher consequences. India’s fight against HIV provides a good example to follow: Cipla, the maker of generic drugs, provided a simple message: Its low-priced drugs treated life-threatening conditions, and this message was... View Details
- 2023
- Article
Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance
By: Alexander O. Everhart, Soumya Sen, Ariel D. Stern, Yi Zhu and Pinar Karaca-Mandic
Importance: Most regulated medical devices enter the U.S. market via the 510(k) regulatory submission pathway, wherein manufacturers demonstrate that applicant devices are “substantially equivalent” to 1 or more “predicate” devices (legally marketed medical devices... View Details
Everhart, Alexander O., Soumya Sen, Ariel D. Stern, Yi Zhu, and Pinar Karaca-Mandic. "Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) Clearance." JAMA, the Journal of the American Medical Association 329, no. 2 (2023): 144–156.
- 19 Sep 2016
- Research & Ideas
Why Isn't Business Research More Relevant to Business Practitioners?
disciplines, where academic research is leading to the development of a second skin that could improve drug delivery or alerting farmers and scientists on how to reduce nitrous oxide emissions from agricultural farming. Harvard Business... View Details
- Research Summary
Clinical Trials as a setting for Health Policy and Management Research
The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
pharma," said HBS professor Regina Herzlinger, moderating a panel discussion titled "Pharma and Biotech—Where does Europe Stand in the World?" The discussion was held at the conference on November 22. At the start of the 1990s, the U.S. and European... View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
coming of age of biotechnology. The disappearance of "blockbuster" drugs could create new management challenges for pharmaceutical companies. — Gary Pisano The prospect is exhilarating, but the road to this brave new biotech... View Details
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
Now that scientists have mapped the human gene, can drug makers map a road to unlimited riches? For John Lechleiter, Executive Vice President of Eli Lilly and Company's Pharmaceutical Products and Corporate Development, there remain more... View Details
Keywords: by Sean Silverthorne
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
Until the close of the last decade, health consumers received much of their knowledge and advice about prescription drugs from their physicians or other health care professionals. Today, pharmaceutical companies are spending several... View Details
Keywords: by Manda Salls
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
as 1994: That year was known among insiders as "The Year of the Placebo." What The Data Says The good news: One hundred thirty drugs can be traced to biotech, said Pisano. (For purposes of discussion during his presentation, he... View Details
- 25 Apr 2005
- Research & Ideas
New Learning at American Home Products
drug business. They relied, however, on licensing rather than building their own in-house capabilities for drug discovery and commercialization. In the low-tech OTC [over-the-counter] sector, they... View Details
- 10 Nov 2020
- Sharpening Your Skills
Research News and Tips: Innovating Across Time Zones
Dany Bahar, Prithwiraj Choudhury, and Britta Glennon. Drugs approved in December are associated with more adverse effects New research reveals that drug approvals surge in the US in December, at month-ends,... View Details
Keywords: by Sean Silverthorne
- 23 Mar 2003
- Research & Ideas
AIDS in Africa—What’s the Solution?
5th Annual Africa Business Conference at Harvard Business School on March 8. Much of the debate over AIDS in Africa has surrounded the high cost of the drugs that have turned the deadly disease into one that patients in the West can now... View Details
Keywords: by Julie Jette
- 09 Aug 2016
- First Look
August 9, 2016
https://www.hbs.edu/faculty/Pages/item.aspx?num=51304 The Impact of the Entry of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic drugs (therapeutic proteins or... View Details
Keywords: Sean Silverthorne
- 09 Apr 2012
- Research & Ideas
Who Sways the USDA on GMO Approvals?
Other Agencies Influence Approvals In the case of procedural legitimacy, the researchers found a strong influence from an unlikely source—the USDA's sister agency, the Food and Drug Administration. In the process of approving GMOs,... View Details
- 30 May 2007
- Research & Ideas
Health Care Under a Research Microscope
Cambridge, Massachusetts, and you will likely be administered beta blockers, a class of drug that's generally recommended after a heart attack. The rate at which that drug is delivered nationwide, however,... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
benefits of sharing data, which can then be used to more quickly identify the most pressing targets and design trials to address them. Innovations to the typical clinical trial model are also being used. In an adaptive platform trial, for example, different View Details
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
by focusing on bigger films that require a bigger commitment." Jeff Robinov believes in blockbusters and his strategy is to create more of them. The pharmaceutical and entertainment industries are similar. R&D costs in both are high. Results are unpredictable.... View Details